









































First detection of the melanoma-predisposing
proline-48-threonine mutation of p16 in Hungarians:
was there a common founder either in Italy or in Hungary?
Márta Szélla,*, Klára Baloghb,*, Attila Dobozya,b, Lajos Keménya,b
and Judit Oláhb
The P48T germ line mutation of p16 was detected in a
Hungarian multiple primary melanoma patient (deceased
at the age of 39) with no affected family members. Genetic
analysis of the patient and his family revealed that the
patient was homozygous for the mutation, whereas his
parents (father currently aged 69 and mother 63), who are
free from any malignancies and atypical moles, are both
heterozygous for the mutation. Our data suggest that the
P48T mutation of p16 is a strong melanoma-predisposing
factor, but the fact that the heterozygous mutant parents
have not yet exhibited melanoma or atypical moles
indicates that the penetrance of this allele might depend
on modifying factors. The rare P48T germ line mutation of
p16 has been reported previously in only four independent
studies, all in patients with Italian ancestry. Here, we first
report the inheritance of the rare P48T mutation of
CDKN2A in a Hungarian family with a homozygous multiple
primary melanoma member and unaffected heterozygous
family members. The question of whether the mutation
detected in Hungary is the result of an independent event,
or migration of the founder mutation occurred at some
time in the past, necessitates further investigations.
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Introduction
The incidence of cutaneous malignant melanoma is
increasing worldwide and familial cutaneous melanoma
accounts for approximately 10% of melanoma cases [1]. It
is well known from dermatological practice that familial
melanoma frequently presents with multiple primary
melanomas and clinically atypical moles, and is diagnosed
at a much younger age than sporadic cutaneous melanoma
[2]. Genetic linkage analysis in large melanoma kindreds
identified a melanoma susceptibility locus on human
chromosome 9p21 [3], germ line mutations of the cyclin-
dependent kinase inhibitor 2a (CDKN2A/p16INK4A)
gene within this chromosomal region are responsible for
melanoma susceptibility [4,5]. Mutations of CDKN2A
are listed in the Human Gene Mutation Database, http://
www.hgmd.cf.ac.uk (accessed 15 August 2006). Some of the
listed mutations, detected worldwide, have been im-
plicated in melanoma susceptibility and their inheritance
has been intensively studied in the affected families [6],
whereas some CDKN2A mutations have been detected
only sporadically, and their association with melanoma
susceptibility has not been demonstrated in distant
ethnic groups. This applies to the P48T mutation of
CDKN2A which has so far been detected in only one
Italian pancreas carcinoma patient [7], one Italian [8] and
one Brazilian [9] melanoma patient, and has been most
extensively studied in a large Italian melanoma-prone
family [10]. Here, we report the inheritance of the rare
P48T mutation of CDKN2A in a Hungarian family with a
homozygous multiple primary melanoma member and
unaffected heterozygous family members.
Patients and methods
A 30-year-old Caucasian male presented at our depart-
ment in 1997 with a thick ulcerated nodular melanoma
(pT3b) in the right femoral region (Fig. 1a). He also
suffered from a sporadic form of multiple atypical mole
syndrome (Fig. 1b and c). At the time of diagnosis of the
primary tumor in the right femoral region which was
already 2 cm in size and bleeding, two early primary
melanomas were also diagnosed on his trunk (indicated
by arrows in Fig. 1b and c). After removal of these three
primary melanomas, he underwent delayed elective
radical node dissection from his right groin. The lymph
node metastases indicated interferon a2b therapy, and he
was treated with 10 million units/3 tw interferon a2b for
3 months. Leucopenia and thrombocytopenia compli-
cated the therapy and the patient refused to continue it.
During the 8-year follow-up period, a further five new
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early melanomas developed. No internal organ involve-
ment was found for 7 years. In 2004, intra-abdominal
lymph node metastases were diagnosed. The patient
received bleomycin, vincristine, lomustine and dacarba-
zine (BOLD) polychemotherapy, which resulted in a
slight regression of the metastatic lump. At the end of
2004, radiation therapy was started for the chemoresis-
tant tumor mass in the iliacal and retroperitoneal regions.
After irradiation, his condition remained satisfactory for
3 months, with regression of the metastatic lymph nodes.
In July 2005, however, intrahepatic metastases were
diagnosed. At the end of 2005, he died from multiple
symptomatic liver, lung and intracranial metastases.
The appearance of multiple primary melanoma at a
relatively young age and the existence of numerous
atypical moles suggested a genetic background in this
patient, and we therefore decided to investigate the
possible involvement of CDKN2A mutations in the
pathogenesis. The genetic analysis of the patient and
consequently his family members was approved by the
local ethics committee. Two millilitres of venous blood
was taken, genomic DNA was isolated by using the
Genomic DNA Purification Kit of Gentra (Minneapolis,
Minnesota, USA), and exons 1a, 1b, 2 and 3 of the
CDKN2A gene were amplified under the previously
reported conditions [11]. The PCR products were
purified with the Quantum Prep PCR Kleen Spin
Columns of Bio-Rad (Hercules, California, USA). Se-
quence analysis revealed a homozygote 142C > A trans-
version, which translates the P48T. The mutation is
detected in exon a, meaning that it affects the fifth
amino acid of the second ankyrin repeat of p16 protein,
but the protein sequence of ARF is unaffected.
After detecting this rare mutation in a homozygous form
in our patient, we conducted genetic analysis of his
parents, his 6-year-old daughter and his wife (Fig. 2a).
The father and the mother, currently aged 69 and 63, had
no history of any malignant diseases and both are free of
any atypical moles. They had no knowledge of con-
sanguinity or the occurrence of familial melanoma among
their relatives. Oral sputum samples were taken from
the family members and genomic DNA was isolated from
the samples with the MagNA Pure Compact system
(Roche, Mannheim, Germany). Exon 1a was sequenced




As demonstrated in Fig. 2b, the patient’s father, mother
and daughter are all heterozygote carriers of the 142C > A
mutation, and the wife of the patient harbors the wild-
type allele. Our results suggest that the patient had
inherited one mutant allele from his father and one from
his mother, and further transmitted the mutant allele to
his daughter.
Germ line mutations in the CDKN2A gene have now
been identified in many hereditary melanoma cases, and
are associated with the appearance of multiple primary
Fig. 1
Clinical presentation of the patient. (a) The thick ulcerated nodular
melanoma (pT3b) in the right femoral region of the patient at the time of
presentation. (b and c) The atypical mole syndrome of the patient is
apparent on his trunk; the arrows indicate two early primary melanomas
diagnosed at the same time as the thick ulcerated nodular melanoma.
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melanomas [4,5]. The gene is composed of four coding
regions: exons 1a, 1b, 2 and 3; exons 1a, 2 and 3 code for
p16 protein, whereas exons 1b, 2 and 3 code for ARF
protein, both inevitable regulators of the cell cycle
[12,13]. Various types of mutations are detected on
CDKN2A, and their association with different malignant
diseases has been documented. Most of the mutations
(67 of the 106 so far registered in HGMD; http://
www.hgmd.cf.ac.uk) are missense or nonsense mutations,
and their pathogenic role in familial and/or multiple
melanoma has been unquestionably demonstrated in
distant ethnic populations. For a few missense and
nonsense CDKN2A mutations [7,14–16], however, the
association with melanoma and/or other malignant
diseases has so far been shown only in certain ethnic
groups. This is the situation with the transition
142C > A, which causes the amino acid change P/T in
codon position 48 (Fig. 2c). This rare CDKN2A germ line
mutation has been reported to date in only four cases. It
was first detected in an Italian pancreatic cancer patient
[7], then in an Italian multiple primary melanoma patient
[8], and subsequently in a Brazilian familial melanoma
patient with Italian ancestors [9]: all three patients were
heterozygous for the P48T mutation. None of the above
studies reported genetic studies on family members, and
the possible association of the CDKN2A P48T mutation
and the disease phenotype in those cases can therefore
not be discussed. The extensive genetic analysis carried
out by Della Torre et al. [10] on a large melanoma-prone
Italian family revealed that the heterozygous carriers
of the P48 T mutation were susceptible not only to
melanoma, but also to other forms of malignancies.
Similarly, the disease association of the CDKN2A
mutation resulting in the P48L amino acid change at
the same codon was demonstrated beyond question [17].
The associated family analysis clearly revealed the
association of this mutation with a very high suscept-
ibility to various types of cancers, including melanoma.
The present case suggests that the CDKN2A P48T
mutation is highly associated with the appearance of
primary multiple melanoma. Our case lends further
support to the multifactorial nature of melanoma predis-
position, where the penetrance of a certain allele might
depend on modifying factors and can be extremely
variable across geographic areas [18], because the
heterozygote mutant parents of the patient, at the ages
of 69 and 63, are so far free of any malignancies or any
atypical nevi, in spite of the fact that both have had a
rural lifestyle, with extensive exposure to sunlight.
Furthermore, it is extremely rare to discover individuals
homozygous for CDKN2A mutations; these cases there-
fore offer an opportunity to study the effects of potential
human null mutations of this ultimate cell cycle
regulatory protein. By studying an endogenous Dutch
family with a strong founder effect, Gruis et al. [19]
observed that homozygous carriers of a small deletion in
exon 2 of CDKN2A did not appear to be more seriously
affected than heterozygous carriers. Taken together,
these results and our present data suggest that CDKN2A
mutations in either the heterozygous or the homozygous
state are strong susceptibility factors for various malig-
nant diseases, but other additional factors, such as
genetic variations of the melanocortin 1 receptor gene
in the case of melanoma, are also needed for manifesta-
tion of the malignancies.
Although the patient’s parents were not aware of
consanguinity in their families, the fact that they both
harbor the rare 142C > A CDKN2A germ line mutation
suggests that there must have been such an event or
events a few generations previously. It is interesting that
the only four previous reports of this mutation involved
Italian patients or a Brazilian patient with Italian
ancestors. The members of the present Hungarian family
are unaware of any Italian family relatives. The question
of whether this mutation is the result of an independent

























Deceased at y: 39
Molecular analysis of the 142C/A CDKN2A variant. (a) The patient
(proband) is individual II:1. His father (individual I:1) and mother
(individual I:2) are free from malignancies and atypical nevi.
(b) Chromatograms showing the 142C/A variants; the individuals in
the patient’s family are listed below the chromatograms according
to their genotype. (c) The C/A transversion at nt 142 leads to the
Pro/Thr amino acid change in codon position 48 of the p16 transcript.
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generations ago from Italy to Hungary, or from Hungary to
Northern Italy, demands further examination.
In conclusion, the case we have presented here has
confirmed that the rare P48T mutation of p16 is a
melanoma-predisposing factor, but our genetic analysis
suggests that the heterozygous status itself is not
causative of malignant disease: other modifying factors
may be needed for the manifestation of these disorders.
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